Multiply Your Moments

PADCEV® + pembrolizumab (Keytruda®) helped adults with advanced* bladder cancer live twice as long after treatment compared to chemotherapy.†

*Cancer that has spread or cannot be removed by surgery.
†Based on a clinical study of 886 adults who had not yet received treatment for advanced bladder cancer, PADCEV with pembrolizumab demonstrated a median overall survival of 32 months vs 16 months with chemotherapy.

WHAT IS PADCEV?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter, or urethra).

- PADCEV may be used with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph when your bladder or urinary tract cancer has spread or cannot be removed by surgery (locally advanced or metastatic).
- PADCEV may be used alone when your bladder or urinary tract cancer has spread or cannot be removed by surgery (locally advanced or metastatic) if you:
  - have received PD-1 or PD-L1 immunotherapy medicine **and** chemotherapy that contains platinum, **or**
  - are not able to receive a chemotherapy that contains cisplatin **and** you have received 1 or more prior therapies.

It is not known if PADCEV is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:

Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

- Target lesions (skin reactions that look like rings)
- Rash or itching that continues to get worse
- Blistering or peeling of the skin
- Painful sores or ulcers in mouth or nose, throat, or genital area
- Fever or flu-like symptoms
- Swollen lymph nodes

See **"What are the possible side effects of PADCEV?"** for more information about side effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

This guide was created to help you get started on PADCEV®

Navigating a treatment journey can feel overwhelming, but learning more about your disease and the treatment options available to you can be empowering. This guide has some of the information you need that may help you to take your next step.

Your treatment choice is personal and important. Depending on where you are on your treatment journey, PADCEV (PAD-sev) may be an option that could help you live longer.

PADCEV is available as a treatment for advanced bladder cancer for **2 different groups of people**. Figuring out which group you belong to depends on the treatment you have already received. Look to the right to see which group you belong to and which type of PADCEV treatment may be right for you:



If this is your first treatment for advanced bladder cancer, your doctor may recommend starting PADCEV in combination with pembrolizumab (Keytruda®)

Pg 6

OR

If you have already received treatment for advanced bladder cancer, your doctor may suggest starting with PADCEV alone

Pg 12

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

What you'll find in this guide

Understanding bladder cancer 4

How advanced bladder cancer is treated 5

If this is your first treatment for advanced bladder cancer:
Learn more about PADCEV® + pembrolizumab **6**

If you have already received treatment for advanced bladder cancer:
Learn more about PADCEV alone **12**

How PADCEV is thought to work in your body 18

Important Safety Information **20**

PADCEV Support Solutions® 23

How to play an active role in your treatment 25

For caregivers: looking after yourself 26

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

What should I know about my disease?

If you're reading this guide, it's likely that you or someone you care for has been diagnosed with locally advanced or metastatic urothelial cancer. What does that mean?

Bladder cancer, or **urothelial cancer**, begins in the cells lining the organs (bladder, ureters, renal pelvis, and urethra) in the urinary system. When the cancer spreads to nearby areas, it is called locally advanced cancer. If it has spread to distant parts of the body, like the lymph nodes or other organs, it is called metastatic cancer.

Bladder cancer that has spread or cannot be removed with surgery is known as *advanced bladder cancer*.

How cancer spreads through the bladder



SELECT SAFETY INFORMATION

Before receiving PADCEV®, tell your healthcare provider about all of your medical conditions, including if you:

- Are currently experiencing numbness or tingling in your hands or feet.
- Have a history of high blood sugar or diabetes.
- Have liver problems.
- Are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
- Are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after the last dose of PADCEV.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

How advanced bladder cancer is treated

If you are dealing with advanced bladder cancer, remember you are not alone. By working with their healthcare team and receiving treatment, many people with advanced bladder cancer are able to improve their health outcomes.

For decades, doctors have used traditional chemotherapy to treat advanced bladder cancer. More recently, exciting treatment options have been approved.

Some of the latest treatment options for advanced bladder cancer include:

Antibody-drug conjugate (ADC)

A type of targeted therapy that works by delivering cell-killing medicine directly to cancer cells. However, it can also affect normal cells and cause side effects.

PADCEV® is a type of ADC therapy.

Immunotherapy

Treatment that uses substances to stimulate or suppress the immune system to help the body fight cancer.

Pembrolizumab (Keytruda®) is a type of immunotherapy.

Combination treatment

Scientists have found that combining different treatments, like ADCs with immunotherapy, can lead to better health outcomes for some patients.

PADCEV + pembrolizumab is an example of a combination treatment.

SELECT SAFETY INFORMATION

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
- You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

BASED ON A CLINICAL STUDY FOR ADVANCED BLADDER CANCER,

PADCEV® + pembrolizumab was shown to help some patients live twice as long as patients who were given chemotherapy*

PADCEV + pembrolizumab (Keytruda®) was studied against chemotherapy in a clinical study that included people who had not yet been treated for advanced bladder cancer

IN THE STUDY:

442 people were given PADCEV in combination with pembrolizumab

vs

444 people were given chemotherapy

DURING THE STUDY

About half of patients treated with PADCEV + pembrolizumab lived longer than 32 months



*Cisplatin- or carboplatin-containing chemotherapy.

The **median overall survival** refers to the length of time from the start of treatment in the study that half of the people in the group were still alive.

SELECT SAFETY INFORMATION

Males with a female sexual partner who is able to become pregnant:

- If your female partner is pregnant, PADCEV can harm the unborn baby.
- You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

BASED ON A CLINICAL STUDY FOR ADVANCED BLADDER CANCER,

PADCEV® + pembrolizumab, when used as a first treatment, may help keep your cancer from growing longer than chemotherapy

People taking PADCEV + pembrolizumab had twice the amount of time without their cancer growing or spreading

The length of time about half of patients were alive without their disease getting worse was **13 months** for PADCEV + pembrolizumab and **6 months** for chemotherapy

2x longer
Median progression-free survival

Median progression-free survival: The length of time from the start of treatment in the study that half of the people in the group were still alive, and their cancer did not grow or spread.

In this study, PADCEV + pembrolizumab were tested against chemotherapy. The results showed that treatment with PADCEV + pembrolizumab led to better health outcomes for patients.

SELECT SAFETY INFORMATION

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

- **Skin Reactions. See "What is the most important information I should know about PADCEV?"**
- **High blood sugar (hyperglycemia).** An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis, and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you get any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

What to expect with the PADCEV® + pembrolizumab treatment schedule

When you receive PADCEV with pembrolizumab (Keytruda®), each treatment cycle is 21 days

Your healthcare professional will decide how many treatment cycles you need, and may do blood tests regularly during treatment.

One dose of PADCEV
is given by intravenous (IV) infusion for 30 minutes, then **one dose of pembrolizumab** or **pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex™)** is given by IV infusion or subcutaneous injection

One dose of PADCEV
is given by IV infusion for 30 minutes

Dose free



For example, if you receive your first dose of PADCEV with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph on a Monday, you would have another dose of PADCEV the following Monday, and then the next Monday would be dose free.

This timeline is only a visual representation of the dosing schedule. It is not meant to be used to track your treatment cycle. Specific days of the week may vary based on your healthcare professional's recommendation.

Talk to your doctor about what your dosing schedule may look like.

For additional dosing information, see the Medication Guides for pembrolizumab and for pembrolizumab and berahyaluronidase alfa-pmph.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Questions for you and your caregiver to ask your healthcare team

How will this treatment affect our daily lives?

How will we know if this treatment is working?

Can lifestyle changes help us manage advanced bladder cancer?

How will you treat side effects that may occur during treatment?

SELECT SAFETY INFORMATION

- **Lung problems.** PADCEV® may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Side effects to watch for when taking PADCEV® in combination with pembrolizumab

To help treat your side effects with PADCEV,

Your doctor may:

Decrease your dose

Temporarily pause your treatment

Completely stop your treatment

Side effects may occur at any time during treatment with PADCEV, **but reporting them early may help manage them more appropriately**.

That is why it is important for you to take an active role in your treatment, and **alert your care team as soon as you experience any side effects**.

In clinical studies for PADCEV, people who experienced side effects may have had a dose reduction, dose hold, or discontinuation to help manage their side effects.

PADCEV may cause serious side effects, including:

- Skin reactions
- High blood sugar (hyperglycemia)
- Lung problems
- Nerve problems
- Eye problems
- Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation)

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Side effects to watch for when taking PADCEV® in combination with pembrolizumab (cont'd)

Not actual patients.

The following are the most common side effects of **PADCEV when used in combination with pembrolizumab (Keytruda®):**

- Changes in liver function and kidney function tests
- Rash
- Increased sugar (glucose) in the blood
- Numbness or tingling in your hands or feet
- Increased lipase (a test done to check your pancreas)
- Decreased white blood cell, red blood cell, and platelet counts
- Tiredness
- Decreased sodium, phosphate, and protein (albumin) in the blood
- Itching
- Diarrhea
- Hair loss
- Decreased weight
- Decreased appetite
- Increased uric acid in the blood
- Increased or decreased potassium
- Dry eye
- Nausea
- Constipation
- Change in sense of taste
- Urinary tract infection

If your healthcare provider prescribes PADCEV in combination with the medicines pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex™), also read the Medication Guide that comes with these medicines for additional important information.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

IF YOU HAVE ALREADY RECEIVED TREATMENT FOR ADVANCED BLADDER CANCER,

Based on a clinical study, PADCEV® may help you live longer than chemotherapy

For people who previously received an immunotherapy medicine and either cisplatin- or carboplatin-containing chemotherapy, PADCEV was shown to help some people live longer

IN THE STUDY:

301 people were given PADCEV

vs

307 people were given chemotherapy*

DURING THE STUDY

About half of patients treated with PADCEV lived longer than 13 months



*Docetaxel, paclitaxel, or vinflunine.

This is called the **median overall survival.** The median overall survival refers to the length of time from the start of treatment in the study that half of the people in the group were still alive.

SELECT SAFETY INFORMATION

- **Nerve problems.** Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

IF YOU HAVE ALREADY RECEIVED TREATMENT FOR ADVANCED BLADDER CANCER,

Based on a clinical study, your cancer may be more likely to respond to PADCEV® than chemotherapy

More people responded to treatment with PADCEV

More than twice as many people treated with PADCEV had their tumors shrink or disappear vs chemotherapy

This is called the **overall response rate.** The overall response rate refers to the percentage of people in a study whose cancer shrinks or disappears (not detectable on tests) within a certain amount of time after treatment. This does not mean the cancer has been cured.

SELECT SAFETY INFORMATION

- **Eye problems.** Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you get dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

What to expect with the treatment schedule when PADCEV® is given alone

When you receive PADCEV alone, each treatment cycle is 28 days

Your healthcare professional will decide how many treatment cycles you need, and may do blood tests regularly during treatment.

PADCEV is given by IV infusion for 30 minutes on days 1, 8, and 15 of a 28-day treatment cycle



For example, if you receive your first dose of PADCEV on a Monday, you would have another dose of PADCEV for each of the next 2 Mondays (for a total of 3 doses of PADCEV), followed by a Monday that would be dose free.

This timeline is only a visual representation of the dosing schedule. It is not meant to be used to track your treatment cycle. Specific days of the week may vary based on your healthcare professional's recommendation.

Not actual patients.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Questions for you and your caregiver to ask your healthcare team

How will this treatment affect our daily lives?

How will we know if this treatment is working?

Can lifestyle changes help us manage advanced bladder cancer?

How will you treat side effects that may occur during treatment?

SELECT SAFETY INFORMATION

- **Leakage of PADCEV® out of your vein into the tissues around your infusion site (extravasation).** If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blistering, peeling skin or discomfort at the infusion site.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Side effects to watch for when taking PADCEV® alone

To help treat your side effects with PADCEV,

Your doctor may:

Decrease your dose

Temporarily pause your treatment

Completely stop your treatment

Side effects may occur at any time during treatment with PADCEV, **but reporting them early may help manage them more appropriately**.

That is why it is important for you to take an active role in your treatment, and **alert your care team as soon as you experience any side effects**.

In clinical studies for PADCEV, people who experienced side effects may have had a dose reduction, dose hold, or discontinuation to help manage their side effects.

PADCEV may cause serious side effects, including:

- Skin reactions
- High blood sugar (hyperglycemia)
- Lung problems
- Nerve problems
- Eye problems
- Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation)

Learn more information about serious side effects in the PADCEV Patient Information.

Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Side effects to watch for when taking PADCEV® alone (cont'd)

Not actual patients.

The following are the most common side effects of **PADCEV when used alone:**

- Increased sugar (glucose) in the blood
- Changes in liver and kidney function tests
- Decreased white blood cell, red blood cell, and platelet counts
- Rash
- Tiredness
- Numbness or tingling in your hands or feet
- Decreased protein (albumin), sodium, and phosphate in the blood
- Hair loss
- Decreased appetite
- Diarrhea
- Nausea
- Itching
- Increased uric acid in the blood
- Dry eye
- Change in sense of taste
- Constipation
- Increased lipase (a blood test done to check your pancreas)
- Decreased weight
- Stomach (abdominal) pain
- Dry skin

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV® is different from traditional chemotherapy

PADCEV is used to treat advanced bladder cancer

It is a type of prescription medicine known as an antibody-drug conjugate, or ADC.

- PADCEV is **different from the chemotherapy or immunotherapy** you may have had before
- PADCEV is thought to work by delivering cell-killing medicine **directly to certain cancer cells.*** However, it can also affect normal cells and cause side effects
- Talk to your healthcare professional about side effects, and see pages 20-22 for information about possible side effects with PADCEV

PADCEV is made of 3 parts:

An **antibody** that attaches to a certain type of protein on the surface of a cell



A **link** that connects the cell-killing medicine to the antibody

Cell-killing medicine that is released inside of the cell

Antibody: A protein most commonly made by the body's immune system. The antibody that makes up PADCEV is produced in a laboratory.

*This is how PADCEV was shown to work in lab studies.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

How PADCEV® is thought to work against cancer in your body

PADCEV is thought to target certain cancer cells with cell-killing medicine



PADCEV attaches to the surface of the cancer cell.



PADCEV enters the cancer cell and releases cell-killing medicine.



The medicine works to damage and kill the cancer cell.

This is how PADCEV was shown to work in lab studies.

PADCEV with pembrolizumab (Keytruda®)

Combines 2 therapies that treat advanced bladder cancer in different ways



PADCEV delivers cell-killing medicine to certain cancer cells.



Pembrolizumab helps prevent certain cancer cells from hiding and allows your immune system to find and fight them.



PADCEV and pembrolizumab each work to treat advanced bladder cancer in different ways.

Please see the pembrolizumab patient Medication Guide for important safety information.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Important Safety Information

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PADCEV®?

PADCEV may cause serious side effects, including:

Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

- Target lesions (skin reactions that look like rings)
- Rash or itching that continues to get worse
- Blistering or peeling of the skin
- Painful sores or ulcers in mouth or nose, throat, or genital area
- Fever or flu-like symptoms
- Swollen lymph nodes

See **"What are the possible side effects of PADCEV?"** for more information about side effects.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

- Are currently experiencing numbness or tingling in your hands or feet.
- Have a history of high blood sugar or diabetes.
- Have liver problems.
- Are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
- Are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after the last dose of PADCEV.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
- You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Males with a female sexual partner who is able to become pregnant:

- If your female partner is pregnant, PADCEV can harm the unborn baby.
- You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Important Safety Information (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV® with certain other medicines may cause side effects.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

- **Skin Reactions. See "What is the most important information I should know about PADCEV?"**
- **High blood sugar (hyperglycemia).** An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis, and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you get any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
- **Lung problems.** PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
- **Nerve problems.** Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
- **Eye problems.** Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you get dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
- **Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation).** If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blistering, peeling skin or discomfort at the infusion site.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Important Safety Information (cont'd)

Your healthcare provider may decrease your dose of PADCEV®, or temporarily or completely stop your treatment with PADCEV if you get severe side effects.

If your healthcare provider prescribes PADCEV in combination with the medicines pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, also read the Medication Guide that comes with these medicines for additional important information.

The most common side effects of PADCEV when used in combination with pembrolizumab include:

- Changes in liver function and kidney function tests
- Rash
- Increased sugar (glucose) in the blood
- Numbness or tingling in your hands or feet
- Increased lipase (a test done to check your pancreas)
- Decreased white blood cell, red blood cell, and platelet counts
- Tiredness
- Decreased sodium, phosphate, and protein (albumin) in the blood
- Itching
- Diarrhea
- Hair loss
- Decreased weight
- Decreased appetite
- Increased uric acid in the blood
- Increased or decreased potassium
- Dry eye
- Nausea
- Constipation
- Change in sense of taste
- Urinary tract infection

The most common side effects of PADCEV when used alone include:

- Increased sugar (glucose) in the blood
- Changes in liver and kidney function tests
- Decreased white blood cell, red blood cell, and platelet counts
- Rash
- Tiredness
- Numbness or tingling in your hands or feet
- Decreased protein (albumin), sodium, and phosphate in the blood
- Hair loss
- Decreased appetite
- Diarrhea
- Nausea
- Itching
- Increased uric acid in the blood
- Dry eye
- Change in sense of taste
- Constipation
- Increased lipase (a blood test done to check your pancreas)
- Decreased weight
- Stomach (abdominal) pain
- Dry skin

PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

PADCEV Support Solutions® is here to help

PADCEV Support Solutions offers access and reimbursement support to help patients like you, who have been prescribed PADCEV®, access their medication.

We can help evaluate your insurance coverage

PADCEV Support Solutions offers information to help you understand your insurance coverage for PADCEV. PADCEV Support Solutions will provide your healthcare professional with a summary of your insurance benefits. We can also help determine if your insurer requires a prior authorization (PA). If your insurer denies a PA request, and your healthcare professional determines that an appeal is appropriate, PADCEV Support Solutions can assist with the appeal process.*

PADCEV Support Solutions offers patient assistance options and financial assistance information

Copay Assistance Program

The PADCEV Copay Assistance Program is for eligible patients who have private commercial health insurance and are not insured by any federal or state healthcare program, including, but not limited to, Medicare, Medicaid, TRICARE, or Veterans Affairs (VA).

Eligible patients may pay as little as $5 per dose and will be enrolled in the program for a 12-month period. Under the Program, eligible patients have an annual maximum copay assistance limit of $25,000 per calendar year. There are no income requirements.†

Patient Assistance Program

The PADCEV Patient Assistance Program provides PADCEV at no cost to uninsured patients who meet the program eligibility requirements.‡

Financial Assistance Information

For patients who need financial assistance to help cover out-of-pocket costs, PADCEV Support Solutions can provide information about other sources of support that may be able to help.

Not an actual patient.

*The healthcare provider remains responsible for providing all clinical information.

†By enrolling in the PADCEV Copay Assistance Program ("Program"), the patient acknowledges that they currently meet the eligibility criteria and will comply with the following terms and conditions: The Program is for eligible patients with commercial prescription insurance for PADCEV® (enfortumab vedotin-ejfv) and is good for use only with a valid prescription for PADCEV. The Program has an annual maximum copay assistance limit of $25,000 per calendar year. After the annual maximum on copay assistance is reached, patient will be responsible for the remaining out-of-pocket costs for PADCEV. **The Program is not valid for patients insured by any state or federal healthcare program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program.** Patients who move from commercial insurance to federal or state prescription health insurance will no longer be eligible, and agree to notify the Program of any such change. This offer is not valid for cash paying patients. Patients agree not to seek reimbursement from any health insurance or third party for all or any part of the benefit received by the patient through the Program. This offer is not conditioned on any past, present, or future purchase of PADCEV. This offer is not transferable, has no cash value, and cannot be combined with any other offer, free trial, prescription savings card, or discount. The full value of the Program benefits is intended to pass entirely to the eligible patient. The benefit available under this Program is valid only for the patient's out-of-pocket medication costs for PADCEV. The benefit is not valid for any other out-of-pocket costs such as medication administration charges or other healthcare provider services. No other individual or entity (including, without limitation, third party payers, pharmacy benefit managers, or the agents of either) is entitled to receive any benefit, discount, or other amount in connection with this Program. **This offer is not health insurance** and is only valid for patients in the 50 United States, Washington DC, and Puerto Rico. This Program is void where prohibited by law. No membership fees. Certain rules and restrictions apply. Astellas reserves the right to revoke, rescind, or amend this offer without notice for any reason (including to ensure that the offer is utilized solely for the patient's benefit).

‡Subject to eligibility criteria. Terms and conditions apply. Void where prohibited by law.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV Support Solutions® is here to help (cont'd)

Call PADCEV Support Solutions at 1-888-402-0627 Monday-Friday, 8:30 AM to 8:00 PM ET, if you have any questions or need assistance.

PADCEV® enfortumab vedotin-ejfv Injection for IV infusion 20 mg & 30 mg vials
SUPPORT® SOLUTIONS

Patient Connect

PADCEV Support Solutions, through the Patient Connect Program, offers additional patient and caregiver support to people like you who have been prescribed PADCEV®. This program helps connect you and your loved ones to educational resources and support based on your particular needs to help you manage your disease and daily life while on treatment.

When you call PADCEV Support Solutions, a trained representative will speak with you to understand the types of challenges you may be facing and will customize a search of various independent local and national organizations* that may provide support and resources for you and your loved ones. Examples may include:

Emotional Support

- Social workers, counseling services, or online communities for you
- Emotional support for your family members and friends

Logistical Support

- Transportation and lodging assistance to get you to/from appointments
- Help with other day-to-day tasks

Informational Support

- Other education and resources about your disease and treatment
- Information on nutrition and self-care

*Support is provided through third-party organizations that operate independently and are not controlled or endorsed by Astellas or Pfizer. Availability of support and eligibility requirements are determined by these organizations.

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

PADCEV® enfortumab vedotin-ejfv Injection for IV infusion 20 mg & 30 mg vials

How to play an active role in your treatment with PADCEV®

Playing an active role in your treatment is important

- Make sure to keep your appointments and stay on schedule
- Talk to your healthcare team about any scheduling concerns
- Reach out to your healthcare team right away if you are feeling unwell or notice any side effects
- Use a journal to keep a daily track of side effects or changes you may experience

Your care team is here to help and support you as you receive treatment. Never hesitate to reach out to them when you need something or notice anything different. The sooner you communicate with them, the better they can help you.



PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

If you are caring for a loved one, look after yourself too

Try to keep these tips in mind as you support your loved one throughout their treatment

It is OK to ask for help

As a caregiver, you may feel like you need to take care of everything, but sometimes you may need support. People may want to help you and the person you care for, but they may not know how. Speak up and ask friends and family members to help out with tasks when you need it.

Make time for yourself and other relationships

Take the time to do something you enjoy. It can also be helpful to spend time with other people in your life who are important to you.

Your health matters too

Being a caregiver will keep you busy. Remember to schedule appointments with your doctor to talk about ways you can stay healthy, such as eating well, regular exercise, and getting enough sleep.

For more information about PADCEV®, please visit PADCEV.com/advanced-bladder-cancer or call 1-888-4PADCEV (1-888-472-3238)

Please see Important Safety Information throughout and read the Patient Information here for more information, including risk of Serious Side Effects.

Visit PADCEV.com/advanced-bladder-cancer/resources and find tools to help support you during your treatment with PADCEV

astellas

Pfizer Oncology

© 2026 Astellas Pharma Inc. or its affiliates and Pfizer Inc. All rights reserved. MAT-US-PAD-2026-00844 08/26
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other trademarks are the property of their respective owners.

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials